Phase I Study of OriC902 in Treatment of Advanced HCC

NCT06891742 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

44

Enrollment

OTHER

Sponsor class

Conditions

HCC

Interventions

DRUG: OriC902

Sponsor

Peking University

Collaborators

[object Object]